Lam Research Corporation $LRCX Stake Decreased by Brentview Investment Management LLC

Brentview Investment Management LLC cut its holdings in shares of Lam Research Corporation (NASDAQ:LRCX) by 1.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 48,443 shares of the semiconductor company’s stock after selling 859 shares during the period. Lam Research makes up about 2.4% of Brentview Investment Management LLC’s investment portfolio, making the stock its 17th largest holding. Brentview Investment Management LLC’s holdings in Lam Research were worth $4,715,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the business. Sava Infond d.o.o. lifted its holdings in Lam Research by 3.1% in the 2nd quarter. Sava Infond d.o.o. now owns 75,250 shares of the semiconductor company’s stock valued at $7,325,000 after acquiring an additional 2,250 shares during the last quarter. Horizon Bancorp Inc. IN bought a new stake in shares of Lam Research in the 2nd quarter worth approximately $389,000. Empowered Funds LLC lifted its stake in Lam Research by 10.5% during the first quarter. Empowered Funds LLC now owns 187,472 shares of the semiconductor company’s stock valued at $13,629,000 after purchasing an additional 17,833 shares during the last quarter. Genus Capital Management Inc. bought a new stake in Lam Research during the second quarter worth approximately $14,476,000. Finally, Cookson Peirce & Co. Inc. acquired a new position in Lam Research in the first quarter worth approximately $607,000. 84.61% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently commented on LRCX. Dbs Bank increased their price objective on Lam Research from $119.40 to $184.20 in a research report on Monday, October 27th. TD Cowen upped their target price on Lam Research from $145.00 to $170.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Needham & Company LLC increased their price target on Lam Research from $150.00 to $160.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. HSBC set a $127.00 price objective on Lam Research and gave the stock a “hold” rating in a report on Tuesday, September 30th. Finally, UBS Group reaffirmed a “buy” rating and set a $175.00 price objective (up from $165.00) on shares of Lam Research in a research note on Tuesday, November 25th. Twenty-six analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $152.17.

Insider Activity at Lam Research

In related news, SVP Vahid Vahedi sold 52,190 shares of the stock in a transaction on Monday, October 13th. The stock was sold at an average price of $138.90, for a total transaction of $7,249,191.00. Following the completion of the sale, the senior vice president directly owned 251,047 shares in the company, valued at approximately $34,870,428.30. This trade represents a 17.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Douglas R. Bettinger sold 40,080 shares of Lam Research stock in a transaction on Friday, November 14th. The shares were sold at an average price of $150.60, for a total value of $6,036,048.00. Following the sale, the chief financial officer directly owned 987,237 shares of the company’s stock, valued at approximately $148,677,892.20. The trade was a 3.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 102,608 shares of company stock valued at $14,916,496. 0.31% of the stock is owned by insiders.

Lam Research Trading Down 0.1%

Shares of NASDAQ LRCX opened at $154.95 on Monday. The company has a current ratio of 2.21, a quick ratio of 1.60 and a debt-to-equity ratio of 0.37. Lam Research Corporation has a one year low of $56.32 and a one year high of $167.15. The business has a 50-day moving average price of $147.23 and a two-hundred day moving average price of $114.99. The firm has a market capitalization of $194.62 billion, a PE ratio of 34.13, a PEG ratio of 1.68 and a beta of 1.87.

Lam Research (NASDAQ:LRCX) last posted its quarterly earnings results on Wednesday, October 22nd. The semiconductor company reported $1.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.04. The business had revenue of $5.32 billion during the quarter, compared to analyst estimates of $5.23 billion. Lam Research had a net margin of 29.66% and a return on equity of 60.60%. The firm’s revenue was up 27.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.86 earnings per share. Lam Research has set its Q2 2026 guidance at 1.050-1.250 EPS. As a group, analysts predict that Lam Research Corporation will post 3.71 earnings per share for the current fiscal year.

Lam Research Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 7th. Stockholders of record on Wednesday, December 3rd will be issued a dividend of $0.26 per share. This represents a $1.04 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Wednesday, December 3rd. Lam Research’s payout ratio is currently 22.91%.

About Lam Research

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.